ATE406917T1 - Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür - Google Patents

Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür

Info

Publication number
ATE406917T1
ATE406917T1 AT02796357T AT02796357T ATE406917T1 AT E406917 T1 ATE406917 T1 AT E406917T1 AT 02796357 T AT02796357 T AT 02796357T AT 02796357 T AT02796357 T AT 02796357T AT E406917 T1 ATE406917 T1 AT E406917T1
Authority
AT
Austria
Prior art keywords
carrier
fine particles
production method
composition containing
active ingredients
Prior art date
Application number
AT02796357T
Other languages
English (en)
Inventor
Kazunori Kataoka
Yoshinori Kakizawa
Original Assignee
Toudai Tlo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toudai Tlo Ltd filed Critical Toudai Tlo Ltd
Application granted granted Critical
Publication of ATE406917T1 publication Critical patent/ATE406917T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Dry Development In Electrophotography (AREA)
  • Electrophotography Configuration And Component (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02796357T 2001-08-27 2002-08-27 Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür ATE406917T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001256125 2001-08-27

Publications (1)

Publication Number Publication Date
ATE406917T1 true ATE406917T1 (de) 2008-09-15

Family

ID=19083982

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796357T ATE406917T1 (de) 2001-08-27 2002-08-27 Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür

Country Status (7)

Country Link
US (1) US7897176B2 (de)
EP (1) EP1431347B1 (de)
JP (2) JP2003523544A (de)
AT (1) ATE406917T1 (de)
CA (1) CA2458837C (de)
DE (1) DE60228742D1 (de)
WO (1) WO2003018690A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003083478A1 (fr) * 2002-04-03 2003-10-09 Japan Science And Technology Agency Face de capteur pour biopuce porteuse de nanoparticules de polyethylene glycolate
WO2007116965A1 (ja) * 2006-04-12 2007-10-18 Toray Industries, Inc. グラフトポリマーとカルシウム化合物とを含む微粒子
EP2082754A4 (de) * 2006-11-11 2012-10-31 Univ Tokyo Knochendefekt-füller, träger mit kontrollierter freisetzung und ihre produktionsverfahren
JP5081439B2 (ja) * 2006-12-07 2012-11-28 独立行政法人科学技術振興機構 造影剤含有有機−無機ハイブリッド型粒子
CA2682135A1 (en) * 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
JP2011010549A (ja) * 2007-10-29 2011-01-20 Univ Of Tokyo ポリエチレングリコールの結合した核酸のコンジュゲートとリン酸カルシウムの有機−無機ハイブリッド型ナノ粒子
JP2010018772A (ja) * 2008-01-25 2010-01-28 Ebara Corp ペグ修飾ハイドロキシアパタイト及びそれを基材とする医薬とその製造方法
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
EP2457588A1 (de) 2010-11-05 2012-05-30 UMC Utrecht Holding B.V. Mikrosphäre mit Lanthanid-Metallkomplex
CN113908137B (zh) * 2021-10-27 2023-04-11 高州市人民医院 一种注射用硬核软膜型纳米缓释递药系统的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517111A (ja) 1991-02-21 1993-01-26 Ricoh Co Ltd 水酸アパタイト超微粒子
US5368869A (en) * 1993-03-09 1994-11-29 Utah State University Foundation Compositions and methods for manufacturing a skim or lowfat milk product with increased creaminess, color, mouthfeel, and taste sensations similar to milk with a higher fat content
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US6939564B2 (en) 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체

Also Published As

Publication number Publication date
JPWO2003018690A1 (ja) 2004-12-09
JP2003523544A (ja) 2003-08-05
CA2458837C (en) 2009-12-15
US7897176B2 (en) 2011-03-01
US20040197360A1 (en) 2004-10-07
CA2458837A1 (en) 2003-03-06
JP4641721B2 (ja) 2011-03-02
WO2003018690A1 (fr) 2003-03-06
EP1431347B1 (de) 2008-09-03
EP1431347A4 (de) 2006-08-30
EP1431347A1 (de) 2004-06-23
DE60228742D1 (de) 2008-10-16

Similar Documents

Publication Publication Date Title
ATE406917T1 (de) Zusammensetzung, enthaltend feine teilchen als träger von biologischen wirkstoffen, und herstellungsverfahren dafür
UA66952C2 (uk) N-(5,7-диметокси[1,2,4]триазоло[1,5-a]піримідин-2-іл)арилсульфонамід, спосіб його одержання, композиція на його основі та спосіб боротьби з небажаною рослинністю
TW289020B (de)
DE69033040D1 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
DE69431660D1 (de) 2-pyridylmethylen-polyazamacrocyclophosphonsäuren, ihre komplexe und derivate zur verwendung als kontrastmittel
DE60139625D1 (de) Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung
YU48701A (sh) Fenilfenantridini sa dejstvom inhibicije pde-iv
DE69434980D1 (de) Stabile bakterizide Proteine, welche die Permeabilität erhöhen und pharmazeutische Zusammensetzungen, diese enthaltend
BR0316886A (pt) Composição, processo para a preparação de uma composição, produto para contraste, usos de uma composição e uso de partìculas magnéticas
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
ES2102743T3 (es) Soluciones estabilizadas de agentes antitumorales de platino (ii).
DE60028152D1 (de) Fester, stabiler und konzentrierter biologisch verdaulicher Komplex von Orthokieselsäure und Prozess zur dessen Herstellung
DE3585865D1 (de) Eine enzymzusammensetzung als verdauungsbeschleuniger bei verschiedenen spiegeln im verdauungskanal und deren herstellungsverfahren.
ES2101953T3 (es) Compuestos de cerio iv organicos y su preparacion y utilizacion.
IT1224405B (it) Composti attivi sul sistema cardiovascolare
DE3750857D1 (de) Imidazolsulfonamid-Derivate, Herbizide und Verfahren zur Bekämpfung von Schadpflanzen.
EP0969095A3 (de) (S)-Hydroxynitrillyasen mit verbesserter Substanzakzeptanz und deren Verwendung
IL108997A0 (en) Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
DE50105413D1 (de) Verfahren zur Racemisierung von optisch aktiven Aminen
SE8304124L (sv) Fluoralkylerade karbapenemderivat
DE60022751D1 (de) Mittel zur stabilisierung von hämoglobinen
BR0015422A (pt) Formulações de droga de liberação prolongada
ATE167869T1 (de) Thiolderivate von gallensäure
DK427388A (da) Farmaceutiske midler indeholdende trapidil samt fremgangsmaade til fremstilling heraf
FR2608044B1 (fr) Composition antibiotique aqueuse a usage veterinaire

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties